Colecalciferol/ibandronic acid - Alvogen Korea

Drug Profile

Colecalciferol/ibandronic acid - Alvogen Korea

Alternative Names: DP-R 206

Latest Information Update: 16 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DreamPharma Corporation
  • Developer Alvogen Korea
  • Class Adjuvants; Antihypercalcaemics; Bisphosphonates; Calcium regulators; Cholestenes; Osteoporosis therapies; Small molecules; Sterols; Vitamin D analogues
  • Mechanism of Action Bone resorption factor inhibitors; Dimethylallyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Postmenopausal osteoporosis

Most Recent Events

  • 18 Feb 2016 Phase-III development is still ongoing in South Korea (NCT01581320)
  • 01 Jan 2013 Phase-III clinical trials in Postmenopausal osteoporosis (including elderly) in South Korea (unspecified route)
  • 06 Apr 2012 Phase-I clinical trials in Postmenopausal osteoporosis (in volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top